Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeOne
Pharma
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
“What is clear is that we have found a better way to target HER2,” an ASCO-invited expert said, referring to Ziihera as better than Herceptin.
Angus Liu
Jan 6, 2026 3:25pm
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Dec 9, 2025 7:30am
Zymeworks pivots to become 'royalty-driven' drugmaker
Nov 18, 2025 8:25am
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
AbbVie, BeOne end BTK inhibitor patent fight
Oct 2, 2025 10:29am
BeOne bags $885M in Royalty deal on Amgen's Imdelltra
Aug 25, 2025 10:34am
